Niche Biopharmaceuticals


Early-stage biotechnology company developing a novel small-molecule therapeutic class described as a coupled anti-infected immunomodulatory therapeutic (CAIT). The company reports broad-spectrum antibacterial and antiviral activity, anti-inflammatory properties, issued composition-of-matter and use patents, a pre-IND interaction with the FDA (May 2024), and an initial clinical focus on atopic dermatitis with plans to support a Phase 1 trial.

Industries

biopharma
health-care
life-science
pharmaceutical

Nr. of Employees

small (1-50)

Niche Biopharmaceuticals

22345 Bracketts Road Shorewood, MN 55331 USA


Patents

Antimicrobial and antiviral sulfur containing glycerol monoester derivatives

US-11873272-B2

View Details

Antimicrobial and antiviral sulfur containing glycerol monoester derivatives

US-11572342-B2

View Details

Antimicrobial and antiviral sulfur containing glycerol monoester derivatives

US-11365176-B2

View Details

Products

Small-molecule new chemical entity for dermatological and anti-infective indications

A novel small-molecule therapeutic class described as a coupled anti-infected immunomodulatory therapeutic with reported broad-spectrum antibacterial and antiviral activity and anti-inflammatory properties. Initial development focus is on atopic dermatitis.

Expertise Areas

  • Small-molecule drug discovery
  • Antimicrobial and antiviral therapeutics
  • Preclinical pharmacology and mechanism-of-action studies
  • Regulatory strategy and FDA pre-IND interactions
  • Show More (2)

Key Technologies

  • Small-molecule NCE synthesis
  • In vitro antibacterial assays
  • In vitro antiviral assays
  • Serial passaging resistance assays
  • Show More (2)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.